Novo Nordisk – The Drug Company Shaping an Entire Nation

Video: WHY THE WORLD CAN'T QUIT THE US DOLLAR?

If you missed the best recent articles:

• Will There Be a US Recession Next Year?

• Why Does America Still Have to Buy Oil?

• FIRST 100 DAYS OF TRUMP 2.0

• Ranking FED Chairs Since 1950

• Mar-a-Lago Deal: How Trump Will Rearrange the World Order

• Business Valuation: DCF & Rule 40

• 5 Historical Asset Bubbles & Lessons for Investors

In the quiet suburb of Bagsværd, Denmark, one name has seemingly become the backbone of the entire economy: Novo Nordisk. Starting as a local insulin manufacturer, the company took nearly a century to rise to global leadership in diabetes and obesity treatment.

Novo's growth story is not only iconic in medicine but also Denmark's real economic power:

• Market cap once exceeded Denmark's entire GDP.

• Contributed 26 billion DKK in taxes in 2024.

• Accounted for ~50% of 2024 GDP growth and 70% of national export revenue.

"In 2024, we served more than 45.2 million people living with serious chronic diseases, while global revenue and profit increased 26% at constant exchange rates." – Lars Fruergaard Jørgensen, CEO

From an insulin specialist, Novo Nordisk has captured over 50% of global insulin supply and gradually expanded into new treatment areas. Stock price growth of +750% from 2016 to mid-2024 clearly reflected market expectations.

However, after a long-term uptrend, the stock has lost half its value in just the past 10 months, losing its European market cap crown to SAP and LVMH.

So is this an attractive buying opportunity – or a growth trap that's run its course?

In this article, Viet Hustler will dissect Novo Nordisk's development journey with you and explore its competitive advantages and business potential:

1. Overview of Novo Nordisk

   1. Formation and Development

   2. Leadership Team

2. Novo Nordisk's Business Model

3. Competitive Landscape Analysis

4. Financial Health Analysis

5. Future Outlook

6. Preliminary Valuation

7. Investment Risks